These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 25406429

  • 1. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS, Cranmer LD.
    BMC Res Notes; 2014 Nov 18; 7():812. PubMed ID: 25406429
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER.
    Invest New Drugs; 2015 Oct 18; 33(5):1040-7. PubMed ID: 26091915
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC.
    BMC Cancer; 2017 Jan 21; 17(1):67. PubMed ID: 28109246
    [Abstract] [Full Text] [Related]

  • 4. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.
    Eur J Haematol; 2010 Mar 21; 84(3):201-11. PubMed ID: 19929977
    [Abstract] [Full Text] [Related]

  • 5. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.
    Cancer Chemother Pharmacol; 2013 May 21; 71(5):1315-23. PubMed ID: 23468082
    [Abstract] [Full Text] [Related]

  • 6. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
    Xu C, Li X, Li T, Wang X, Yang Y, Xiao L, Shen H.
    Asian Pac J Cancer Prev; 2011 May 21; 12(11):2951-7. PubMed ID: 22393970
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB, Naiditch JA, Clark S, Chu F, Madonna MB.
    J Pediatr Surg; 2012 Jun 21; 47(6):1267-71. PubMed ID: 22703804
    [Abstract] [Full Text] [Related]

  • 8. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
    Huang JJ, Li ZM, Huang Y, Huang Y, Tian Y, He XX, Xiao J, Lin TY.
    Invest New Drugs; 2012 Feb 21; 30(1):223-35. PubMed ID: 20960030
    [Abstract] [Full Text] [Related]

  • 9. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
    Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA.
    PLoS One; 2015 Feb 21; 10(11):e0142704. PubMed ID: 26571493
    [Abstract] [Full Text] [Related]

  • 10. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.
    Br J Haematol; 2010 May 21; 149(4):518-28. PubMed ID: 20201941
    [Abstract] [Full Text] [Related]

  • 11. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
    Dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL.
    Oncol Rep; 2014 Feb 21; 31(2):955-68. PubMed ID: 24316794
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
    Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
    BMC Cancer; 2017 May 16; 17(1):334. PubMed ID: 28511645
    [Abstract] [Full Text] [Related]

  • 13. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
    Lim HJ, Wang X, Crowe P, Goldstein D, Yang JL.
    Anticancer Res; 2016 Nov 16; 36(11):5765-5771. PubMed ID: 27793898
    [Abstract] [Full Text] [Related]

  • 14. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001.
    Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, Sasagawa S, Araki N, Ueda T, Itoh K, Myoui A, Yoshikawa H.
    Cancer Lett; 2014 May 28; 347(1):114-22. PubMed ID: 24491407
    [Abstract] [Full Text] [Related]

  • 15. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A.
    Exp Hematol; 2008 Apr 28; 36(4):443-50. PubMed ID: 18343280
    [Abstract] [Full Text] [Related]

  • 16. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 28; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 17. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB.
    Gynecol Oncol; 2016 Jun 28; 141(3):570-579. PubMed ID: 27017985
    [Abstract] [Full Text] [Related]

  • 18. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    Endocrine; 2016 Feb 28; 51(2):274-82. PubMed ID: 26219406
    [Abstract] [Full Text] [Related]

  • 19. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, Jove R, Forman SJ, Yen Y, Kirschbaum MH.
    Cancer Res; 2011 Jun 01; 71(11):3912-20. PubMed ID: 21502403
    [Abstract] [Full Text] [Related]

  • 20. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.
    Cancer; 2011 Sep 15; 117(18):4141-54. PubMed ID: 21387274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.